Case Studies

Context & Objective

• Numerous therapeutic antibodies have been approved for a variety of targets; however, this modality is encumbered with significant challenges such as target specific selectivity deficits, escalated therapy costs, and or autoimmune responses.
• Considering these constraints, one of our clients identified a pressing requirement for alternative therapeutic approaches within specific domains. As a remedial strategy, we proposed the development of a small molecule inhibitor for therapeutically validated target , offering a viable substitute to circumvent these limitations.

Approach & Solution

• Our methodology employed using RxAgentAI to formulate a small molecule inhibitor by identifying structure of protein and its druggable pocket for a validated target.
• This process entailed a detailed analysis of the structural and topological principles that regulate protein functionality which helped in subsequently designing and synthesis of the inhibitory compounds.
• Leveraging our internal cadre of distinguished Scientists, Medicinal Chemists, Computational Biologists, and proprietary technological assets, we engineered small molecule inhibitors targeting an array of receptors.
• Candidate compounds were assessed computationally to match the “binding” and “inhibitory” properties of existing biologic therapeutic agents.
• These compounds were then evaluated through functional screening assays.

Outcome & Impact

As a result, development of new chemical entities has potential to address unmet medical needs across various therapeutic landscapes, providing safe and cost-efficient treatment options for patients to biologic antagonists. Our recommendations and outcomes helped secure funding for client for further development of the assets.